If the lower proportion of CMV-specific CD8 cells in AD patients reflects a partially impaired cellular immunity, present before or in early stages of the AD pathophysiological process, CMV reactivation in brain macrophages or vascular endothelial cells could be contributing to local inflammation and disease progression. This evidence concerns the gene CD8A and Alzheimer disease.